Feb 17, 2014 | Digital Pathology, Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Pathology, Uncategorized
Experts are excited about the swift development of wireless remote monitoring of patients; companies expected to develop sensors that incorporate a wide range of biomarkers
Some experts predict that the era of wireless, remote monitoring of patients is almost upon us. It will require pathologists and medical laboratory professionals to learn a new acronym: MBAN, which stands for medical body area network.
There is keen interest in remote wireless monitoring systems. The concept is to free patients from the hospital bed and allow continuous remote monitoring, regardless of where the patient is located. For this reason, in just a few years and in many local markets, opportunities are likely to be ripe for pathologists and clinical laboratory teams to have a role in managing wireless medical devices that use MBANs. (more…)
Nov 11, 2010 | Digital Pathology, Laboratory News, Laboratory Pathology
Second-opinion consults will be handled by UPMC’s sub-specialist pathologists
Here’s a unique anatomic pathology collaboration that crosses international borders and will utilize state-of-the-art digital pathology technology to support subspecialty pathologist consultations between the United States and China.
In recent weeks, the University of Pittsburgh Medical Center (UPMC) disclosed that it will provide a range of healthcare services to what is only described as “the largest pathology laboratory in Shanghai.” Of particular interest to pathologists and clinical laboratory managers in the United States, is the fact that pathologists at UPMC will provide second opinion anatomic pathology services to this as-yet-unnamed Chinese pathology laboratory.
(more…)
Feb 25, 2010 | Laboratory News, Laboratory Pathology
Both companies are important suppliers to clinical laboratories and research labs
In recent days, news surfaced that Thermo Fisher Scientific Inc. (NYSE: TMO) was offering $6 billion to acquire Millipore Corporation (NYSE:MIL). Neither company has confirmed the offer, but yesterday Millipore issued a statement that its Directors were “evaluating strategic options.”
Should Thermo Fisher acquire Millipore, or should Millipore find another buyer, it will mean the same thing: more consolidation among vendors who are major suppliers for clinical pathology laboratories. This would continue a global consolidation trend among clinical laboratory suppliers and in vitro diagnostics (IVD) manufacturers that reaches back more than a decade and a half.
(more…)
